Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis

Atherosclerosis

Volumn 247, Issue , 2016, Pages 161-169

  Amor, Antonio J ^a   Catalan, Marta ^b   Pérez, Antonio ^c,d   Herreras, Zoe ^b   Pinyol, Montserrat ^b   Sala Vila, Aleix ^a,d   Cofán, Montserrat ^a,d   Gilabert, Rosa ^a   Ros, Emilio ^a,d   Ortega, Emilio ^a,d  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Carotid ultrasound; Diabetes; Lipoproteins; Nuclear magnetic resonance spectroscopy; Preclinical atherosclerosis

Indexed keywords

LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL WALL; BODY FAT; BODY MASS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; AGED; ASYMPTOMATIC DISEASE; ATHEROSCLEROTIC PLAQUE; BLOOD; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; COMMON CAROTID ARTERY; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; DYSLIPIDEMIAS; EARLY DIAGNOSIS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ODDS RATIO; PREDICTIVE VALUE; RISK FACTOR; SPAIN;

AGED; ASYMPTOMATIC DISEASES; BIOMARKERS; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EARLY DIAGNOSIS; FEMALE; HUMANS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SPAIN;

EID: 84959037037     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.02.014     Document Type: Article

References (39)

1. Sarwar N., Gao P., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. Emerging Risk Factors Collaboration.
2. Seshasai S.R.K., Kaptoge S., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 2011, 364:829-841. Emerging Risk Factors Collaboration.
3. Temelkova-Kurktschiev T.S., Koehler C., Leonhardt W., Schaper F., Henkel E., Siegert G., Hanefeld M. Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors. Diabetes Care 1999, 22:333-338.
4. Sigurdardottir V., Fagerberg B., Hulthe J. Preclinical atherosclerosis and inflammation in 61-year-old men with newly diagnosed diabetes and established diabetes. Diabetes Care 2004, 27:880-884.
5. Li L.-X., Zhao C.-C., Ren Y., Tu Y.-F., Lu J.-X., Wu X., Zhang W.X., Zhu J.A., Li M.F., Yu L.B., Bao Y.Q., Jia W.P. Prevalence and clinical characteristics of carotid atherosclerosis in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study. Cardiovasc. Diabetol. 2013, 12:18.
6. Catalan M., Herreras Z., Pinyol M., Sala-Vila A., Amor A.J., de Groot E., Gilabert R., Ros E., Ortega E. Prevalence by sex of preclinical carotid atherosclerosis in newly diagnosed type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 2015, 25:742-748.
7. Taskinen M.-R., Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 2015, 239:483-495.
8. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we?. Diabetologia 2015, 58:886-899.
9. Moin D.S., Rohatgi A. Clinical applications of advanced lipoprotein testing in diabetes mellitus. Clin. Lipidol. 2011, 6:371-387.
10. Mallol R., Rodriguez M.A., Brezmes J., Masana L., Correig X. Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. Prog. Nucl. Magn. Reson. Spectrosc. 2013, 70:1-24.
11. Gómez-Ambrosi J., Silva C., Catalán V., Rodríguez A., Galofré J.C., Escalada J., Valentí V., Rotellar F., Romero S., Ramírez B., Salvador J., Frühbeck G. Clinical usefulness of a new equation for estimating body fat. Diabetes Care 2012, 35:383-388.
12. Mallol R., Amigó N., Rodríguez M.A., Heras M., Vinaixa M., Plana N., Rock E., Ribalta J., Yanes O., Masana L., Correig X. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. J. Lipid Res. 2015, 56:737-746.
13. Junyent M., Cofán M., Núñez I., Gilabert R., Zambón D., Ros E. Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1107-1113.
14. Sala-Vila A., Cofán M., Pérez-Heras A., Núñez I., Gilabert R., Junyent M., Mateo-Gallego R., Cenarro A., Civeira F., Ros E. Fatty acids in serum phospholipids and carotid intima-media thickness in Spanish subjects with primary dyslipidemia. Am. J. Clin. Nutr. 2010, 92:186-193.
15. Touboul P.-J., Hennerici M.G., Meairs S., et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc. Dis. Basel Switz. 2007, 23:75-80.
16. Wagenknecht L.E., Zaccaro D., Espeland M.A., Karter A.J., O'Leary D.H., Haffner S.M. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1035-1041.
17. Adiels M., Olofsson S.-O., Taskinen M.-R., Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1225-1236.
18. Garvey W.T., Kwon S., Zheng D., Shaughnessy S., Wallace P., Hutto A., Pugh K., Jenkins A.J., Klein R.L., Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462.
19. Festa A., Williams K., Hanley A.J.G., Otvos J.D., Goff D.C., Wagenknecht L.E., Haffner S.M. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005, 111:3465-3472.
20. Wang J., Stančáková A., Soininen P., Kangas A.J., Paananen J., Kuusisto J., Ala-Korpela M., Laakso M. Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J. Intern. Med. 2012, 272:562-572.
21. Nobécourt E., Jacqueminet S., Hansel B., Chantepie S., Grimaldi A., Chapman M.J., Kontush A. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005, 48:529-538.
22. Shalaurova I., Connelly M.A., Garvey W.T., Otvos J.D. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab. Syndr. Relat. Disord. 2014, 12:422-429.
23. Sekikawa A., Ueshima H., Sutton-Tyrrell K., Kadowaki T., El-Saed A., Okamura T., Takamiya T., Ueno Y., Evans R.W., Nakamura Y., Edmundowicz D., Kashiwagi A., Maegawa H., Kuller L.H. Intima-media thickness of the carotid artery and the distribution of lipoprotein subclasses in men aged 40 to 49 years between whites in the United States and the Japanese in Japan for the ERA JUMP study. Metabolism 2008, 57:177-182.
24. Mora S., Szklo M., Otvos J.D., Greenland P., Psaty B.M., Goff D.C., O'Leary D.H., Saad M.F., Tsai M.Y., Sharrett A.R. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007, 192:211-217.
25. Otvos J.D., Mora S., Shalaurova I., Greenland P., Mackey R.H., Goff D.C. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J. Clin. Lipidol. 2011, 5:105-113.
26. Mackey R.H., Greenland P., Goff D.C., Lloyd-Jones D., Sibley C.T., Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 2012, 60:508-516.
27. Qi Y., Fan J., Liu J., Wang W., Wang M., Sun J., Liu J., Xie W., Zhao F., Li Y., Zhao D. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. J. Am. Coll. Cardiol. 2015, 65:355-363.
28. Zaid M., Fujiyoshi A., Miura K., et al. High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in Japanese men. Atherosclerosis 2015, 239:444-450.
29. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
30. Wu L., Parhofer K.G. Diabetic dyslipidemia. Metabolism 2014, 63:1469-1479.
31. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., Wood A.M., Lewington S., Sattar N., Packard C.J., Collins R., Thompson S.G., Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. Emerging Risk Factors Collaboration.
32. Crosby J., Peloso G.M., et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 2014, 371:22-31. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood InstituteNational Heart, Lung, and Blood Institute.
33. Jørgensen A.B., Frikke-Schmidt R., Nordestgaard B.G., Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 2014, 371:32-41.
34. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
35. Spence J.D. Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am. J. Cardiol. 2002, 89:10B-15B. discussion 15B - 16B.
36. Brook R.D., Bard R.L., Patel S., Rubenfire M., Clarke N.S., Kazerooni E.A., Wakefield T.W., Henke P.K., Eagle K.A. A negative carotid plaque area test is superior to other noninvasive atherosclerosis studies for reducing the likelihood of having underlying significant coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26:656-662.
37. Zhang L., Qiao Q., Tuomilehto J., Janus E.D., Lam T.H., Ramachandran A., Mohan V., Stehouwer C.D., Dong Y., Nakagami T., Onat A., Söderberg S. DECODE/DECODA Study Group. Distinct ethnic differences in lipid profiles across glucose categories. J. Clin. Endocrinol. Metab. 2010, 95:1793-1801.
38. Bays H.E., Jones P.H., Brown W.V., Jacobson T.A. National lipid association Annual summary of clinical lipidology 2015. J. Clin. Lipidol. 2014, 8:S1-S36. National Lipid Association.
39. Garber A.J., Abrahamson M.J., Barzilay J.I., et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr. Pract. 2013, 19:536-557.